Background: In the US and around the world, cataracts are the primary cause of blindness. The present study assessed efficacy of 0.07% bromfenac ophthalmic solution in patients with cataract surgery. Materials & Methods: 120 patients scheduled for cataract surgery of both genders were divided into 2 groups. In group I patients, Bromfenac 0.07% and in group II, placebo was administered once daily starting one day prior to cataract surgery, on the day of the procedure, and for 14 days following the procedure. Results: The percentage of subjects with summed ocular inflammation score (SOIS) of grade 0 at day 1 was 2.6% and 1.6%, at day 3 was 10.4% and 3.4%, at day 8 was 35.7% and 16.8% and at day 15 was 49.5% and 25.6% in group I and II respectively. The difference was significant (P< 0.05). The percentage of subjects with summed ocular pain score of grade 0 at day 1 was 70.2% and 51.6%, at day 3 was 81.5% and 53.4%, at day 8 was 90.2% and 61.8% and at day 15 was 92.5% and 63.2% in group I and II respectively. The difference was significant (P< 0.05). Conclusion: In participants who had undergone cataract surgery, bromfenac ophthalmic solution 0.07% dosed once day was clinically safe and effective in treating ocular inflammation and pain when compared to a placebo.